Compare BBOT & PRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBOT | PRA |
|---|---|---|
| Founded | 2016 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | BBOT | PRA |
|---|---|---|
| Price | $12.33 | $24.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $23.80 | $22.50 |
| AVG Volume (30 Days) | 194.2K | ★ 405.2K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | ★ $1,120,385,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.24 |
| P/E Ratio | ★ N/A | $36.59 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.50 | $13.90 |
| 52 Week High | $14.87 | $24.41 |
| Indicator | BBOT | PRA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.76 |
| Support Level | N/A | $24.14 |
| Resistance Level | N/A | $24.27 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 30.30 |
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.